Miravirsen - Roche
Alternative Names: Liver-specific microRNA-122 antagonist - Roche; LNA-antimiR™-122; miR-122 antagonist - Roche; Miravirsen sodium; SPC-3649Latest Information Update: 07 Sep 2021
At a glance
- Originator Santaris Pharma
- Developer Roche
- Class Antivirals; Oligonucleotides; RNA
- Mechanism of Action MIRN122 microRNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis C
Most Recent Events
- 07 Sep 2021 Discontinued - Phase-I for Hepatitis C (In volunteers) in Netherlands, Denmark (IV)
- 07 Sep 2021 Discontinued - Phase-II for Hepatitis C (Treatment-experienced) in USA, Puerto Rico (SC)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in Denmark (IV, Infusion)